Related Experiment Video

Updated: Aug 16, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

High frequency somatic mutations in RASSF1A in nasopharyngeal carcinoma

Zhi-Gang Pan1, V I Kashuba, Xiao-Qiong Liu

  • 1Department of Experimental Research, Cancer Center, Sun Yat-sen University, Guangzhou, China.

Cancer Biology & Therapy
|August 13, 2005
PubMed

Insights

The Ras association domain family 1A (RASSF1A) gene is frequently mutated in nasopharyngeal carcinoma (NPC) tumors. These mutations, along with promoter methylation, likely contribute to NPC development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The 3p21.3 chromosomal region, containing the RASSF1A tumor suppressor gene, frequently undergoes loss in various cancers, including nasopharyngeal carcinoma (NPC).
  • Mechanisms like chromosomal alterations and epigenetic changes are implicated in RASSF1A inactivation.

Purpose of the Study:

  • To investigate the frequency and types of somatic mutations in the RASSF1A gene in NPC tissues.
  • To assess the correlation between RASSF1A mutations and promoter methylation in NPC.

Main Methods:

  • Utilized a PCR-cloning-sequencing strategy to analyze RASSF1A mutations in NPC tumor tissues and matched peripheral blood lymphocytes.
  • Assessed RASSF1A promoter methylation in the same NPC tissue samples.

Main Results:

  • A high incidence of RASSF1A mutations was observed in 74% of NPC cases (17/23), with 35 distinct mutations identified.
  • Mutations included transitions, transversions, and deletions, leading to various amino acid changes, including nonsense, frameshift, and missense mutations.
  • A similarly high rate (74%) of RASSF1A promoter methylation was detected, with no significant correlation found between mutation and methylation status.

Conclusions:

  • Multiple mechanisms contribute to RASSF1A inactivation in NPC.
  • RASSF1A plays a critical role in the development of nasopharyngeal carcinoma.

More Related Videos

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas07:00

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Published on: February 28, 2019

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...